News | Remote Monitoring | July 11, 2023

First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study

FIRE1 announced the start of the first U.S. clinical study of its remote heart failure monitoring system, designed to provide unique insights to the care team and alert to deteriorating patient conditions for the almost 10M Americans with HF

FIRE1 announced the start of the first U.S. clinical study of its remote heart failure monitoring system, designed to provide unique insights to the care team and alert to deteriorating patient conditions for the almost 10M Americans with HF

July 11, 2023 — FIRE1 announced that the first U.S. patients have been successfully implanted with its FIRE1 System for remote heart failure monitoring in an Early Feasibility Study. The study will assess FIRE1’s novel solution to improve outcomes for heart failure patients. The first patient was implanted at Austin Heart, Texas, where Kunjan Bhatt, MD, leads the study as Principal Investigator and Thomas McMinn, MD, performed the implants.

“We are delighted to announce the first implants in the U.S. of this new, transformative technology for patients with chronic heart failure,” said Dr. Bhatt. “The procedures were very straightforward, and the patients tolerated the procedure well without any complications. We are excited to use the unique insights we will get from this device to improve patient care. On behalf of Austin Heart, the Heart Hospital of Austin, and St. David’s Healthcare, we are honored to launch research of this technology in the U.S.”

“This device may offer a completely new way of measuring chronic heart failure,” said Nir Uriel, MD, National Principal Investigator for the study and Director of Heart Failure, Heart Transplant and Mechanical Circulatory Support programs at New York-Presbyterian. “The data gathered outside of the U.S. has been promising, and we look forward to studying its use in the U.S.”

Dr. Uriel is also a Professor of Medicine in the Division of Cardiology at Columbia University Vagelos College of Physicians and Surgeons and an adjunct Professor of Medicine in the Greenburg Division of Cardiology at Weill Cornell Medicine.

FIRE1 CEO and President Conor Hanley said, “We have made great clinical progress in Europe and I am proud to announce the milestone of first cases in the U.S., the largest healthcare market in the world. I want to express my gratitude to all the patients who continue to put their faith in us and their care teams who are working tirelessly to bring this important technology to market. The FIRE1 team is committed to its mission of helping millions of patients living with heart failure to get their normal lives back, and today is an important step forward on this journey.”

For more information: www.fire1foundry.com


Related Content

News | Heart Failure

May 22, 2024 — New research from The Cooper Institute and partners at University of Texas (UT) Southwestern Medical ...

Home May 22, 2024
Home
News | Heart Failure

April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College ...

Home April 30, 2024
Home
News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
Subscribe Now